07:04 AM EDT, 04/03/2025 (MT Newswires) -- BeiGene ( ONC ) said Thursday that it will discontinue the development of ociperlimab for lung cancer after an independent review panel recommended that the trial be stopped because the potential treatment was unlikely to improve survival outcomes.

BeiGene ( ONC ) said no new safety concerns were identified during the trial.

Shares of the company were down 1.7% in recent Thursday premarket activity.